Allogene Therapeutics Announces Participation in September Investor Conference
05 sept. 2023 08h30 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Appoints Earl Douglas as General Counsel
14 août 2023 08h30 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
02 août 2023 16h02 HE
|
Allogene Therapeutics, Inc.
Presented Long-Term Data for an Allogeneic CD19 CAR T Product Candidate in Relapsed/Refractory Large B Cell Lymphoma (LBCL) at the American Society of Clinical Oncology (ASCO) Annual Meeting and...
Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
26 juil. 2023 08h30 HE
|
Allogene Therapeutics, Inc.
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage...
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
15 juin 2023 09h30 HE
|
Allogene Therapeutics, Inc.
Presentation Includes Data on All 33 CAR T-Naïve Patients Treated with the Alloy™ Manufactured Material and Recaps Data on 12 Large B Cell Lymphoma Patients Treated with Phase 2 Dose RegimenResults...
Allogene Therapeutics Announces Departure of Chief Financial Officer
14 juin 2023 08h00 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
09 juin 2023 18h25 HE
|
Allogene Therapeutics, Inc.
Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous TherapiesPresentation...
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
03 juin 2023 09h00 HE
|
Allogene Therapeutics, Inc.
Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation...
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
24 mai 2023 08h30 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
11 mai 2023 11h50 HE
|
Allogene Therapeutics, Inc.
Data Will Also Be Presented in a Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2023 SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) --...